Targets › KLKB1
8 programs from 8 companies in 12 trials: 5 Phase 3, 4 Phase 2, 2 Phase 4, 1 Phase 1; Immunology, Neurology, Ophthalmology; next expected readout Nov 2026.
Participates in the surface-dependent activation of blood coagulation. Activates, in a reciprocal reaction, coagulation factor XII/F12 after binding to negatively charged surfaces. (UniProt, P03952)
Open in Phaseline: the race on KLKB1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bernstein Clinical Research Center | Lanadelumab Plasma kallikrein inhibitor | KLKB1 | Phase 4 | Angioedema | Sep 2027 |
| KalVista Pharmaceuticals | sebetralstat (KVD900) Plasma kallikrein inhibitor | KLKB1 | Phase 4 | Hereditary Angioedema | Nov 2027 |
| BioCryst Pharmaceuticals | Berotralstat Plasma kallikrein inhibitor | KLKB1 | Phase 3 | Hereditary Angioedema | Feb 2027 |
| Pharvaris Netherlands | Deucrictibant Plasma kallikrein inhibitor | KLKB1 | Phase 3 | Hereditary Angioedema (HAE); Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) | Jun 2027 |
| ADARx Pharmaceuticals | ADX-324 siRNA duplex oligonucleotide targeting KLKB1 | KLKB1 | Phase 3 | Hereditary Angioedema; Hereditary Angioedema (HAE) | Nov 2027 |
| Kyowa Kirin | KHK4951 Kallikrein-bradykinin pathway inhibitor | KLKB1 | Phase 2 | Neovascular Age-Related Macular Degeneration (nAMD); Diabetic Macular Edema (DME) | Nov 2026 |
| DiaMedica Therapeutics | DM199 Recombinant human tissue kallikrein (rinvecalinase alfa) - serine protease that activates | KLKB1 | Phase 2 | Acute Stroke | Dec 2026 |
| General Hospital of Shenyang Military Region | Human Urinary Kallidinogenase Tissue kallikrein that converts kininogen into kallidin and kinins; promotes vascular endo | KLKB1 | Phase 2 | Ischemic Stroke | Sep 2027 |
Hereditary Angioedema (4) Hereditary Angioedema (HAE) (2) Neovascular Age-Related Macular Degeneration (nAMD) (1) Diabetic Macular Edema (DME) (1) Ischemic Stroke (1) Angioedema (1) Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) (1) Acute Stroke (1)
small molecule (4), mixed (1), other (1), protein or peptide (1), antibody (1)
Kyowa Kirin (1) KalVista Pharmaceuticals (1) BioCryst Pharmaceuticals (1) ADARx Pharmaceuticals (1) General Hospital of Shenyang Military Region (1) Bernstein Clinical Research Center (1) Pharvaris Netherlands (1) DiaMedica Therapeutics (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.